Literature DB >> 12917419

Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.

Armelle Calipel1, Gaelle Lefevre, Celio Pouponnot, Frédéric Mouriaux, Alain Eychène, Frédéric Mascarelli.   

Abstract

The BRAF gene, encoding a mitogen-activated protein kinase kinase kinase, is mutated in several human cancers, with the highest incidence occurring in cutaneous melanoma. The activating V599E mutation accounted for 80% of all mutations detected in cutaneous melanoma cell lines. Reconstitution experiments have shown that this mutation increases ectopically expressed B-Raf kinase activity and induces NIH3T3 cell transformation. Here we used tumor-derived cell lines to characterize the activity of endogenous mutated B-Raf protein and assess its specific role in transformation. We show that three cell lines (OCM-1, MKT-BR, and SP-6.5) derived from human choroidal melanoma, the most frequent primary ocular neoplasm in humans, express B-Raf containing the V599E mutation. These melanoma cells showed a 10-fold increase in endogenous B-RafV599E kinase activity and a constitutive activation of the MEK/ERK pathway that is independent of Ras. This, as well as melanoma cell proliferation, was strongly diminished by siRNA-mediated depletion of the mutant B-Raf protein. Moreover, blocking B-RafV599E-induced ERK activation by different experimental approaches significantly reduced cell proliferation and anchorage-independent growth of melanoma cells. Finally, quantitative immunoblot analysis allowed us to identify signaling and cell cycle proteins that are differentially expressed between normal melanocytes and melanoma cells. Although the expression of signaling molecules was not sensitive to U0126 in melanoma cells, the expression of a cluster of cell cycle proteins remained regulated by the B-RafV599E/MEK/ERK pathway. Our results pinpoint this pathway as an important component in choroidal melanoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917419     DOI: 10.1074/jbc.M308709200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Role of MSK1 in the malignant phenotype of Ras-transformed mouse fibroblasts.

Authors:  Beatriz Pérez-Cadahía; Bojan Drobic; Paula S Espino; Shihua He; Soma Mandal; Shannon Healy; James R Davie
Journal:  J Biol Chem       Date:  2010-11-10       Impact factor: 5.157

2.  O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma.

Authors:  Nicolas Penel; Corinne Delcambre; Xavier Durando; Stéphanie Clisant; Mohamed Hebbar; Sylvie Negrier; Charles Fournier; Nicolas Isambert; Frédéric Mascarelli; Frédéric Mouriaux
Journal:  Invest New Drugs       Date:  2008-06-13       Impact factor: 3.850

3.  FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.

Authors:  Olivier E Pardo; Claudia Wellbrock; Umme K Khanzada; Muriel Aubert; Imanol Arozarena; Sally Davidson; Frances Bowen; Peter J Parker; V V Filonenko; Ivan T Gout; Neil Sebire; Richard Marais; Julian Downward; Michael J Seckl
Journal:  EMBO J       Date:  2006-06-29       Impact factor: 11.598

4.  Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression.

Authors:  Laurie S Spofford; Ethan V Abel; Karen Boisvert-Adamo; Andrew E Aplin
Journal:  J Biol Chem       Date:  2006-06-29       Impact factor: 5.157

5.  The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence.

Authors:  Charlotte Lemech; Jeffrey Infante; Hendrik-Tobias Arkenau
Journal:  Ther Adv Med Oncol       Date:  2012-03       Impact factor: 8.168

6.  Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth.

Authors:  Mee-Hyun Lee; Zunnan Huang; Dong Joon Kim; Sung-Hyun Kim; Myoung Ok Kim; Sung-Young Lee; Hua Xie; Si Jun Park; Jae Young Kim; Joydeb Kumar Kundu; Ann M Bode; Young-Joon Surh; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2013-02-27

7.  Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms.

Authors:  Isabelle Hmitou; Sabine Druillennec; Agathe Valluet; Carole Peyssonnaux; Alain Eychène
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

8.  Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Authors:  Nabil Amirouchene-Angelozzi; Fariba Nemati; David Gentien; André Nicolas; Amaury Dumont; Guillaume Carita; Jacques Camonis; Laurence Desjardins; Nathalie Cassoux; Sophie Piperno-Neumann; Pascale Mariani; Xavier Sastre; Didier Decaudin; Sergio Roman-Roman
Journal:  Mol Oncol       Date:  2014-06-13       Impact factor: 6.603

9.  Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation.

Authors:  Hiraku Itadani; Shinji Mizuarai; Hidehito Kotani
Journal:  Curr Genomics       Date:  2008       Impact factor: 2.236

10.  Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.

Authors:  Ana Preto; Joana Gonçalves; Ana P Rebocho; Joana Figueiredo; Ana M Meireles; Ana S Rocha; Helena M Vasconcelos; Hugo Seca; Raquel Seruca; Paula Soares; Manuel Sobrinho-Simões
Journal:  BMC Cancer       Date:  2009-10-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.